People
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
Polyphor AG announced the appointment of Frank Weber, M.D., as Chief Medical and Development Officer, effective September 1, 2019.
Biotech and pharma companies tap new members of executive leadership teams and boards.
Pharnext SA announced the appointment of Peter Collum as Chief Financial Officer and Chief Business Officer.
Contract research organization jobs may not seem as appealing as working in R&D but it can have a lot of advantages—including plenty of career opportunities.
We interviewed Georges Belfort, Ph.D., who is an Institute Professor at Rensselaer Polytechnic Institute and Board Chair of the Society for Biological Engineering. In the interview, Dr. Belfort explained the main fields within engineering and how biochemical engineers are unique.
The Society for Clinical Research Sites announced the finalists for the 2019 Asia-Pac Site Patient Recruitment Innovation Award.
MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer.
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Two well-known scientists, Margaret Hamburg, co-chair of the WHO’s international advisory committee on human genome-editing, and Victor Dzau, president of the U.S. National Academy of Medicine, told STAT in separate interviews this weekend that they were extremely concerned about Denis Rebrikov’s plans.
PRESS RELEASES